metaPreg - Ethosuximide (All indications) during pregnancy

Ethosuximide (All indications)

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)	2.81 [1.07, 7.41]	0%	8 studies	49,640	58	not evaluable	ROB	5.07 [1.34; .]
Major congenital malformations	3.05 [1.12, 8.33]	0%	8 studies	49,634	58	not evaluable	ROB	5.55 [1.48; .]
Congenital heart defects	4.26 [0.38, 47.27]	0%	2 studies	9	12	not evaluable	ROB	-
Hypospadias	4.12 [0.37, 45.30]	0%	2 studies	9	12	not evaluable	ROB	-
Neural Tube Defects	18.80 [1.26, 279.89]	0%	2 studies	2	12	not evaluable	ROB	37.09 [1.84; .]
6 non statistically significant endpoints reported in only one study
Growth parameters and prematurity
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
3 non statistically significant endpoints reported in only one study
Neonatal disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Withdrawal syndrome / Neonatal abstinence syndrome / Poor neonatal adaptation	-	-	0 study					-
Neuro-developmental disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
1 non statistically significant endpoints reported in only one study